GFH375

Phase 3Small molecule

GGenfleet Therapeutics (Shanghai) Inc.

GFH375 is one of 37 small molecule programs targeting Pancreatic Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic CancerActive, not recruiting

KRAS G12DNot yet recruiting

Metastatic Pancreatic CancerRecruiting

Pancreatic CancerPhase 3

Active, not recruiting

KRAS G12DPhase 3

Not yet recruiting

Metastatic Pancreatic CancerPhase 3

Recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

GFH375

GGenfleet Therapeutics (Shanghai) Inc.

Phase 3

1 2

Gemzar

GGynecologic Oncology Group

Byetta

1 4

ABI-007

Bristol-Myers Squibb

Preclinical

2 5

Thiazolidinediones

Sanofi

Preclinical

1 6

Sulfonylureas

Eli Lilly

Preclinical

1 7

Alpha-Glucosidase Inhibitors

Sanofi

Preclinical

1 8

Active Comparator

Moderna

Preclinical

1 9

Chemotherapy Agents

Takeda

Preclinical

1 10

Meglitinides

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 3Recruiting

Metastatic Pancreatic Cancer

NCT07262567

Q4 2028

Phase 1/2Recruiting

Patients With Advanced Solid Tumors

NCT06500676

Q2 2031

Phase 3Not yet recruiting

KRAS G12D

NCT07668752

Clinical

Trials by Indication[1]

Patients With Advanced Solid Tumors1 trial

A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations

Recruiting·GGenfleet Therapeutics (Shanghai) Inc.·Phase 1/2·NCT06500676·407 enrolled

Pancreatic Cancer1 trial

A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer

Withdrawn·GGenfleet Therapeutics (Shanghai) Inc.·Phase 2·NCT07026916

Metastatic Pancreatic Cancer1 trial

A Multicenter, Open-Label, Randomized Controlled Phase III Study to Compare the Efficacy and Safety/Tolerability of GFH375 Monotherapy Versus Investigator's Choice of Chemotherapy in Patients With Previously Treated KRAS G12D-Mutant Metastatic Pancreatic Cancer

Recruiting·GGenfleet Therapeutics (Shanghai) Inc.·Phase 3·NCT07262567·320 enrolled

KRAS G12D1 trial

A Phase III, Randomized, Open-Label, Multicenter Study to Evaluate GFH375 Versus Docetaxel in Participants With Locally Advanced and Unresectable or Metastatic Non-Small Cell Lung Cancer With KRAS G12D Mutation Failed Prior Standard Therapy

Not yet recruiting·GGenfleet Therapeutics (Shanghai) Inc.·Phase 3·NCT07668752·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for GFH375. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GFH375 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GFH375. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Genfleet Therapeutics (Shanghai) Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GGenfleet Therapeutics (Shanghai) Inc.

GFH375

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q4 2028

Q2 2031

Trials by Indication[1]

Patients With Advanced Solid Tumors1 trial

Pancreatic Cancer1 trial

Metastatic Pancreatic Cancer1 trial

KRAS G12D1 trial

References

Drug Info

Quick Facts

Related News